BeiGene commences dosing in Phase II trial of BGB-A317 to treat urothelial cancer
Global biotechnology company BeiGene has commenced dosing patients in a new Phase II trial of its investigational anti-PD-1 antibody, BGB-A317, in patients with urothelial cancer (UC), more commonly known as bladder cancer, in China.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Bladder Cancer | Cancer | Cancer & Oncology | China Health | Pharmaceuticals